New drug could cut IV nutrition needs for short bowel patients

NCT ID NCT06973304

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a drug called teduglutide in 13 Chinese adults with short bowel syndrome who rely on IV nutrition. Participants get a daily injection for 24 weeks to see if it reduces their need for IV support. The study also checks safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
teduglutide (a drug that helps the intestines absorb more nutrients)
What this could lead to
If it works, this could help people with short bowel syndrome reduce their dependence on intravenous nutrition, improving daily life.
What could go wrong
This is a small, early-phase trial with only 13 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Affiliated Jinling Hospital, Medical School of Nanjing University

    RECRUITING

    Nanjing, Jiangsu, 210016, China

  • Beijing Tsinghua Changgung Hospital

    RECRUITING

    Changping, Beijing Municipality, 102218, China

  • Peking Union Medical College Hospital

    RECRUITING

    Dongcheng, Beijing Municipality, 100730, China

  • Zhongshan Hospital, Xiamen University

    COMPLETED

    Siming, Xiamen, 361004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.